Frentizole Therapy of Active Systemic lupus Erythematosus
dc.contributor.author | Kay, Donald R. | en_US |
dc.contributor.author | Valentine, Thomas V. | en_US |
dc.contributor.author | Walker, Sara Ellen | en_US |
dc.contributor.author | Valentine, Merilee H. | en_US |
dc.contributor.author | Bole, Giles G. | en_US |
dc.date.accessioned | 2006-04-28T16:22:18Z | |
dc.date.available | 2006-04-28T16:22:18Z | |
dc.date.issued | 1980-12 | en_US |
dc.identifier.citation | Kay, Donald R.; Valentine, Thomas V.; Walker, Sara E.; Valentine, Merilee H.; Bole, Giles G. (1980)."Frentizole Therapy of Active Systemic lupus Erythematosus." Arthritis & Rheumatism 23(12): 1381-1387. <http://hdl.handle.net/2027.42/37743> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/37743 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7006613&dopt=citation | en_US |
dc.description.abstract | Frentizole is a benzimidazoleurea that has immunosuppressive properties in mice. Eleven steroid-treated patients with active systemic lupus erythematosus received frentizole (150-350 mg/day) in combination with stable or decreasing doses of prednisone in an open label trial. Nine patients completed at least one 21-to 75-day course of therapy with this drug. Clinical parameters of disease improved in 8 of these 9 patients. Mean DNA binding decreased by 28%, mean CH50 increased by 20%, and mean absolute lymphocyte and T cell counts decreased by 25-26%. Granulocytopenia was not observed. Three patients developed reversible hepatic toxicity. Clinical and serologic improvement was noted in 3 patients who accepted a second 90-day course of frentizole therapy. | en_US |
dc.format.extent | 584298 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Rheumatology | en_US |
dc.title | Frentizole Therapy of Active Systemic lupus Erythematosus | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Professor of Internal Medicine; University of Michigan Medical School ; Department of Medicine, Division of Immunology and Rheumatology, N403 University of Missouri Medical Center, Columbia, Missouri 65212 | en_US |
dc.contributor.affiliationum | Professor of Internal Medicine; University of Michigan Medical School | en_US |
dc.contributor.affiliationum | Professor of Internal Medicine; University of Michigan Medical School | en_US |
dc.contributor.affiliationum | Professor of Internal Medicine; University of Michigan Medical School | en_US |
dc.contributor.affiliationum | Professor of Internal Medicine; University of Michigan Medical School | en_US |
dc.identifier.pmid | 7006613 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/37743/1/1780231209_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/art.1780231209 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.